Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged 2022
Will Celgene and Dr. Reddy’s settle the Revlimid dispute now that Bristol Myers is at the table?

Celgene ($CELG) has announced plans to be acquired by Bristol Meyers Squibb ($BMY).  A settlement conference is scheduled in the Hatch-Waxman patent case between Celgene and Dr. Reddy’s on January 10, 2019.  Now that Bristol Meyers is at the table, will the parties be able to reach a settlement that couldn’t be reached before?

Read More
Markman AdvisorsCelgene, CELG, Bristol-Meyers Squibb, Bristol, BMY, Revlimid, Inter Partes Review, IPR, patent, Dr. Reddy's, Natco, lenalidomide, polymorph, 2022, REMS, Hatch-Waxman, generic, ANDA, Zachary Silbersher, SilbersherComment